That's a disgrace. Favus should be very proud of himself.
A good objective discussion is always welcomed and key to biotech investing success. A fictitious hit piece (imo) intended to drive the stock price down in order for some to cover and profit is another.
As you say, time will tell who is right about Ponatinib.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.